Navigation Links
Bionovo Announces 2010 Highlights and Year-End Financial Results
Date:3/15/2011

s.

As of December 31, 2010, cash, cash equivalents and short-term investments totaled approximately $2.6 million compared to $15.9 million at December 31, 2009. The decrease is due to the public offering completed in October of 2009 resulting in net proceeds of $17.4 million, whereas the public offering completed in October 2010 generated net proceeds of $2.5 million. The net cash used in operating activities for 2010 was $14.2 million, compared with $13.3 million in 2009.

2011 GuidanceOn February 10th, the Company laid out key milestones for 2011, which are reiterated here:Manufacture of drug material at higher potency for clinical and non-clinical testing.

Early first quarter. Completed.Conduct a 40 patient, 28-day "tolerability" trial at higher doses planned for later studies.

Late first quarter, early second quarter.Non-clinical study for toxicity in rodents.

Late first quarter, early second quarter.Manufacture of clinical material for Phase 3 study, using FDA-approved commercial process.

Second quarter.Complete contracts, IRB approval and training at U.S. clinical sites for the Phase 3 study.

First and second quarter.Initiate patient recruitment and screening in the Phase 3 study.

End of the second quarter.Initiate dosing in the Phase 3 study.

Early in the third quarter.Data Safety Monitoring Board interim reviews of Phase 3 data.

Five reviews are planned during the course of the Phase 3 study.Completion of recruitment for the Phase 3 study.

Anticipated by the end of the second quarter, 2012.Data available from the Phase 3 study.

Anticipated by the end of the fourth quarter, 2012.Conference CallBionovo will conduct a conference call and webcast to review the Company's financial results and plans for 2011. Interested parties can access the call by dialing 1-888-428-7458, or can listen via a live audio only webcast, which can be found at '/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
2. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
3. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
4. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
5. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
6. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
7. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
8. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
9. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
10. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
11. Bionovo to Raise $3 Million Through Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... clinical studies evaluating potential new medicines in the ... upcoming 2014 European Society of Medical Oncology (ESMO) ... Spain . Data being presented include results ... and efficacy of veliparib (ABT-888), a poly (adenosine ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... SILVER SPRING, Md., March 25, 2011 The U.S. Food ... patients with late-stage (metastatic) melanoma, the most dangerous type ... ) Melanoma is the leading cause ... cases of melanoma were diagnosed in the United States ...
... CoreLab Partners, Inc , the global entity resulting ... is set to attend and actively participate in several ... two weeks. "The legacy of our organization ... physicians, scientists and operational personnel have provided to the ...
Cached Medicine Technology:FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 2FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 3CoreLab Partners Collaborates at Worldwide Industry Conferences 2
(Date:9/22/2014)... 2014 PreDiabetes Centers , a ... with companies to help employees learn their risk for ... as part of a collaboration with the American Diabetes ... , PreDiabetes Centers Medical Director Alan Hopkins, MD, ... Austin on Tuesday, October 21st to discuss the epidemic ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... have known that bacterial pneumonia can raise your risk of ... actually invade and kill heart cells, increasing the chances of ... scientists report. In mice, monkeys and human heart ... the bacteria, and they tried a vaccine that might one ...
(Date:9/22/2014)... 2014 At the 10th Clinton ... Nutrition Partnership (SNP) announced the successful launch of ... Cardiovascular Risk Reduction Program for Women. The announcement ... mitigate their risk of heart disease through a ... plan for addressing significant global challenges made by ...
(Date:9/22/2014)... 2014 TweetMyJobs, a global ... today an agreement with HealthcareSource, the leading ... healthcare industry. The agreement gives HealthcareSource clients ... recruiting solutions directly from within HealthcareSource Position ... healthcare organizations. The partnership provides TweetMyJobs additional ...
(Date:9/22/2014)... MAINE AND BOSTON -- In a collaboration that ... advance cancer research and patient care and accelerate ... Beth Israel Deaconess Medical Center (BIDMC) have established ... institutions, presidents announced today. , A recently signed ... Center to establish a comprehensive relationship in the ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
... could help prevent complications for pregnant women with the ... the 20th week of pregnancy and is characterized by ... the urine. In severe cases it can lead to ... the mother to suffer a series of potentially fatal ...
... embryo transfer instead of a double embryo transfer during ... births without substantially lowering live births, // according to ... than 36 and compared the two approaches of in ... at least one live birth and rates of multiple ...
... nearly 15 million people worldwide. Problems with a ... sneezing, laughing, or lifting heavy objects. Austrian researchers ... with their own stem cells, which they say ... involves removing stem cells from a patient's arm, ...
... that stem cell therapy is effective in treating pigs ... cells from one pig's bone marrow and injecting them ... heart's function to its original condition. ,Researchers studied ... and half of them received therapy. They found injecting ...
... According to a recent study researchers say autistic boys with ... suffering from a language-related disorder known as Specific Language Impairment ... specialists better understand autism and how to choose the best ... MRI scans to look at Broca’s area -- a key ...
... new study the healthiest environment for your child at bedtime ... at night may put children at risk for leukemia.// ... night workers and an increased risk for breast cancer, further ... factor for leukemia. ,Researchers have determined that light at ...
Cached Medicine News:
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Medicine Products: